To Increase Patient Access
End Brain Cancer Mobile App to download your number one tool for navigating this disease.

Post Category: Awareness

April 1, 2024
Advancing Hope: The Mission of the Ivy Brain Tumor Center

The Ivy Brain Tumor Center recognizes the profound impact of brain cancer, a disease for which effective treatments remain elusive. Their mission is to instill hope in patients grappling with this condition by spearheading research and development initiatives aimed at discovering and delivering much-needed medications. Despite the discontinuation of large-scale funding for brain cancer research […]

Read More
November 21, 2023
A Grateful November: Celebrating Family Caregivers

In the spirit of Thanksgiving, November becomes a canvas for expressions of gratitude. It's a time to spotlight the often-overlooked heroes among us—family caregivers. These remarkable individuals selflessly carry emotional, physical, and financial responsibilities to safeguard their loved ones on challenging health journeys. Let's take a moment to honor and celebrate these caregivers who give […]

Read More
November 16, 2023
 IGV-001 Phase 2b Clinical Trial

Imvax is conducting a clinical trial to assess the safety and efficacy of IGV-001, an autologous biologic-device combination product in GBM patients.

Read More
October 2, 2023
Oncoheroes Gains FDA Approval for Pediatric Cancer Drug Trials

In a groundbreaking development for pediatric oncology, Oncoheroes Biosciences, Inc. has received the FDA's green light to proceed with two crucial clinical trials. This milestone opens the door to exploring potential drug treatments for young cancer patients, offering newfound hope in the fight against childhood cancer. The U.S. Food and Drug Administration (FDA) recently granted […]

Read More
September 6, 2023
More Great News For The Fight Against GBM!

Northwest Biotherapeutics has applied for approval to market DCVax®, a personalized immune therapy, for the treatment of Glioblastoma.

Read More
August 14, 2023
Ask for Gleolan Before Brain Tumor Resection

Gleolan is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.

Read More
December 3, 2022
"20 Years of Increasing Patient ACCESS” to Specialists, Advanced Treatment Options, INCLUDING Treatments that are Standard of Care or FDA Approved that Patients are NOT Offered, Diagnostics and Clinical Trials

The End Brain Cancer Initiative (EBCI) and I are once again thrilled to have this platform to increase patient education, awareness & outreach to the global brain tumor community and to the general public with the goal of increasing their direct access to top brain tumor specialists at brain tumor centers of excellence, multiple treatment options/diagnostics and clinical trials.

Read More
August 1, 2022
DISEASE EDUCATION: The End Brain Cancer Initiative (EBCI) this month is sharing with you information related to a very rare disease that only affects @ 1,500 people in the U.S. annually. This disease is known as PCNSL

PROSPECT is an open-label, Phase II study evaluating the efficacy, safety, and pharmacokinetics of an investigational oral medicine called Tirabrutinib (ONO-4059), for patients with primary central nervous system lymphoma (PCNSL).

Read More
July 20, 2022
July 20th is National GBM Awareness Day

Your support is essential to ensuring that the unmet needs of the brain tumor community continue to be heard and addressed. Together, we can advocate for patients and families today, while fueling research with the potential to become the treatments and cures of tomorrow.

Read More
May 7, 2022

Imaging Biometrics (IB) has been developing imaging analysis software for primary brain tumors for close to 30 years. Recently, their imaging software was used to assess treatment response in a pre-clinical study of Gallium Maltolate.

Read More
February 8, 2022
“Incisionless Surgery” Treatment Approach:
Metabolic Targeting of GBM

This month’s CURE MAG Cover Tip brought to you by the End Brain Cancer Initiative (EBCI) and through our patient advocacy and disease education partnership with CURE, focuses on turning Glioblastoma Multiforme (GBM) from a deadly disease into a chronic managed disease.

Read More
February 2, 2022

This month’s Advocacy & Disease Education Cover Tip is shedding a light on a neuro-surgical FDA-approved imaging agent known as Gleolan Brain Dye/Aminolevulinic Acid HCI. The benefit of Gleolan is that it helps neurosurgeons to see “high grade gliomas”.

Read More
1 2 3 4


Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
corporate partners
upcoming events
About us
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram